Cargando…

Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass

PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Francisco Heine Ferreira, de Castro, Heladio Feitosa, Babadopulos, Rodrigo Feitosa de Albuquerque Lima, Rocha, Hermano Alexandre Lima, Rocha, José Lima de Carvalho, de Moraes, Manoel Odorico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585928/
https://www.ncbi.nlm.nih.gov/pubmed/30785510
http://dx.doi.org/10.1590/s0102-865020190010000009
_version_ 1783428806284935168
author Machado, Francisco Heine Ferreira
de Castro, Heladio Feitosa
Babadopulos, Rodrigo Feitosa de Albuquerque Lima
Rocha, Hermano Alexandre Lima
Rocha, José Lima de Carvalho
de Moraes, Manoel Odorico
author_facet Machado, Francisco Heine Ferreira
de Castro, Heladio Feitosa
Babadopulos, Rodrigo Feitosa de Albuquerque Lima
Rocha, Hermano Alexandre Lima
Rocha, José Lima de Carvalho
de Moraes, Manoel Odorico
author_sort Machado, Francisco Heine Ferreira
collection PubMed
description PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. RESULTS: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). CONCLUSION: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis.
format Online
Article
Text
id pubmed-6585928
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
record_format MEDLINE/PubMed
spelling pubmed-65859282019-07-02 Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass Machado, Francisco Heine Ferreira de Castro, Heladio Feitosa Babadopulos, Rodrigo Feitosa de Albuquerque Lima Rocha, Hermano Alexandre Lima Rocha, José Lima de Carvalho de Moraes, Manoel Odorico Acta Cir Bras ORIGINAL ARTICLES PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. RESULTS: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). CONCLUSION: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019-02-14 /pmc/articles/PMC6585928/ /pubmed/30785510 http://dx.doi.org/10.1590/s0102-865020190010000009 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle ORIGINAL ARTICLES
Machado, Francisco Heine Ferreira
de Castro, Heladio Feitosa
Babadopulos, Rodrigo Feitosa de Albuquerque Lima
Rocha, Hermano Alexandre Lima
Rocha, José Lima de Carvalho
de Moraes, Manoel Odorico
Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title_full Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title_fullStr Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title_full_unstemmed Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title_short Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
title_sort ursodeoxycholic acid in the prevention of gallstones in patients subjected to roux-en-y gastric bypass
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585928/
https://www.ncbi.nlm.nih.gov/pubmed/30785510
http://dx.doi.org/10.1590/s0102-865020190010000009
work_keys_str_mv AT machadofranciscoheineferreira ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass
AT decastroheladiofeitosa ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass
AT babadopulosrodrigofeitosadealbuquerquelima ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass
AT rochahermanoalexandrelima ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass
AT rochajoselimadecarvalho ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass
AT demoraesmanoelodorico ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass